通向营收的产业资源对接
我们为你引荐正在澳大利亚寻求采购、投资或共建的行业领袖,并全程参与直到达成实质合作。第6周和第11周各安排一轮一对一会面。
- 会面前进行访谈准备与演练
- 对接采购、工程和监管部门的具名联系人
- Industry partners across pharma, robotics and AI, named on this page
实际案例
100万美元
我们为一家被投企业牵线一家中国上市材料制造商,最终促成的是100万美元的正式客户合同,而不仅仅是一份谅解备忘录。
为期12周、由风投主导并获Innovation Victoria支持的预加速器,培养新一代活跃于AI、机器人与自动化前沿的澳大利亚及亚太深科技创始人。
问题不在科学本身,而在于不知道谁会买单、他们愿意付多少钱,以及投资人如何为你所承担的风险定价。这正是这十二周要解决的。
Each Cohort 1 team is a Victorian deep tech founder or research spinout. Most are at prototype or MVP stage.

Low-cost electrochemical biosensor that detects blood biomarkers for early disease diagnosis.
MM
Point-of-care strip test for late-onset preeclampsia, built on a patented biomarker.

Rapid multiomic blood test for decentralised cancer diagnostics, with results in about two hours.

Stem-cell-derived exosome therapeutics for chronic inflammatory skin conditions.

Regulatory T-cell engineering for autoimmune disease, developing in vivo reprogramming to cut cell-therapy manufacturing cost.
NB
Drug-delivery device for insulin pens.
RL
Sensor-equipped inhaler spacer that captures objective breathing data in children aged one to five.

Machine-learning platform that predicts a drug candidate's ADMET behaviour at atom level, before it is synthesised.
Acoustic AI models of real-world sound under physical conditions, delivered to developers via SDK and API.
HN
Low-cost, real-time hyperspectral imaging that combines insect-eye optics and AI to identify materials in agriculture and manufacturing.

Patented co-production of sustainable aviation fuel and PHA bioplastics from Pongamia feedstock.
QDT
Fab-lite short-wave infrared imaging: prints quantum-dot sensors onto standard industrial backplanes, then scales the same process to compact optical receivers.
CC
End-of-life solar panel recycling that recovers intact silicon wafers and about 99% of the silver.

Electrified modular reactor that uses electromagnetic heating to convert methane and CO₂ into syngas.
Each master brings deep experience in one part of the journey, from drug development and diagnostics to manufacturing, commercialisation, government and market entry into China.

Founder & CEO, SYNthesis Med Chem
Inventor of one of only two FDA-approved small-molecule drugs to originate from Australia, with 16+ drug patents.

CEO & Founder, JustPartnering
25+ years in CEO and consulting roles. Has founded six biotech companies and specialises in partnering pharmaceutical assets and technologies with multinational pharma.

Senior Manager, Startups and Commercialisation, DJSIR
Victorian Department of Jobs, Skills, Industry and Regions, working closely with Innovation Victoria on innovation policy.

Executive Director, Agentel · CEO, Vortair
35+ years commercialising research IP, advanced materials and manufacturing technologies, with over $200M raised.

Executive General Manager, Advanced Manufacturing Readiness Facility (AMRF)
Former Director, Global Manufacturing Operational Excellence at Cochlear; previously at ResMed. Industry Advisory Board, Monash University Faculty of Robotics & Automation. Former Head of Deep Technology, Cicada Innovations.

Co-founder & former Chief Scientist, BCAL Diagnostics (ASX)
Board Director, BioNSW. Helped shape Australia's national diagnostics strategy.

Former National CEO, Australia China Business Council (ACBC) · Lead, Greater China & North Asia, Global Victoria
Led ACBC, Australia's peak Australia–China business body, as National CEO for three years. Now leads Victoria's trade and investment engagement across Greater China and North Asia.

Independent Non-Executive Director, Clarity Pharmaceuticals (ASX: CU6)
25 years of global leadership across diagnostics, pharma and medtech, most recently as Managing Director of Roche Diagnostics Australia. Chair, SwissCham.
Listed in alphabetical order by surname. More masters to be announced.
Cohort 1 teams work directly with global industry and technology leaders through sessions, technical access and introductions.



Listed in alphabetical order.
Boson's investment team uses the same two tools in due diligence. In Collider, every team builds its own in the Collider portal and keeps refining them for all 12 weeks.
价值驱动树
这是我们投资团队在尽职调查中使用的分解方法:这项事业要产生回报,必须成立哪些前提条件,层层拆解直到每个分支都是可验证的假设。你将在第1周搭建自己的价值驱动树,第2周用它揭示技术风险,第9周再将该风险对应到能够帮助化解它的投资人类型。

In the Collider portal, illustrated with a demo company (Uber).
价值链分析
你在全球价值链中处于什么位置、谁在你周围撅取利润,以及这些参与者中谁是合作伙伴、客户、用户或竞争对手。它能告诉你该访谈谁、你的市场真正价值几何,以及在 Collider Sessions 中哪些产业伙伴值得你投入时间。
As-is: the chain today

To-be: the position you could take

In the Collider portal, illustrated with a demo company (Uber).
我们为你引荐正在澳大利亚寻求采购、投资或共建的行业领袖,并全程参与直到达成实质合作。第6周和第11周各安排一轮一对一会面。
实际案例
100万美元
我们为一家被投企业牵线一家中国上市材料制造商,最终促成的是100万美元的正式客户合同,而不仅仅是一份谅解备忘录。
多数项目只是帮你自动化行政事务,而我们睬准的是研发周期本身:仪器搭建、仿真、数据管道与实验设计。从第4周起,技术合作伙伴的一名工程师将每周与学员团队协作。
实际呈现
一次会议,完成需求梳理
带来你研发流程中最耗时的那部分工作。离开时它已被明确规格、估算成本,并可直接交给工程师执行。
把澳大利亚的技术带入亚洲市场,正是 Boson 所做的事。对多数深科技企业而言,第一位付费客户和制造产能往往就在亚洲,因此这必须从第1周就纳入规划。
项目结束后
亚洲落地计划
结业学员可申请部分资助的落地名额:一个软着陆基地,用于开展首批试点项目并在当地与合作伙伴会面。
项目分三个环环相扣的阶段进行。每一节课都注重实操,每项产出都是创始人下周就能带给客户、投资人或董事会的成果。
打磨论点。压力测试技术风险,明确切入点,并将科研语言转化为风险投资人与首批客户都能理解的语言。
与具名买家和具名投资人展开真实的探索周期。同步搭建财务模型、技术路线图与监管计划,而非按顺序推进。
把前期工作转化为势能。创始人将敲定设计合作伙伴、打磨融资叙事,并在对撞机路演日向私密投资人展示。
第一期招募活跃于先进智能与三大高杠杆领域交汇处的创始人。每条赛道都配有专属实战课、导师与客户资源。
诊断、药物研发、手术机器人、临床AI与智能治疗方案——并系统性地引导临床证据、医保报销与监管路径。
工业自动化、工厂感知、材料与智能生产系统——与澳大利亚及亚太制造业运营者对接。
电网智能、储能、气候建模,以及重工业的电气化——并拥有进入公用事业、基础设施与政府渠道的清晰路径。
波色对撞机的设计初衷,是让入选的创始人真正代表未来十年澳大利亚与亚太深科技人才的来源——STEM领域的女性、移民社区的第一代创业者、原住民创业者,以及在主要资本城市创新枢纽之外从事研究的人。
初审申请材料在筛选时不显示姓名、机构或人口统计信息,确保论点本身的说服力才是决定因素。
与女性STEM网络、多元文化商会、原住民商业网络及区域创新枢纽建立积极合作关系。
混合出席方式、可回放的课程录像、面向区域创始人的差旅支持,以及一支能真实反映我们希望吸引的创始人群体的导师团队。
波色对撞机首期招募现已开放申请。如果你是活跃于AI、机器人或自动化前沿的科研或技术型创始人,我们期待你的加入。
Thanks — you're on the Cohort 2 list. We'll be in touch when applications open in April 2027.
中国市场进入
市场进入尽调、客户与合作伙伴对接,以及覆盖上海与粤港澳大湾区的本地落地支持——面向所有澳大利亚科技企业,不限于波色投资组合。